Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failureAssociated ...
Kantata today announced that it was recognized as a Leader in the IDC MarketScape: Worldwide AI-Enabled Professional Services Automation Applications (PSA) 2025-2026 Vendor Assessment (Doc US50655623 ...
Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback